Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia
Authors:
- Nimitha R. MathewNMNimitha R. Mathew
- Janaki M. VinnakotaJVJanaki M. Vinnakota
- Petya ApostolovaPAPetya Apostolova
- Daniel ErnyDEDaniel Erny
- Shaimaa HamarshehSHShaimaa Hamarsheh
- Geoffroy AndrieuxGAGeoffroy Andrieux
- Jung-Seok KimJKJung-Seok Kim
- Kathrin HankeKHKathrin Hanke
- Tobias GoldmannTGTobias Goldmann
- Louise Chappell-MaorLCLouise Chappell-Maor
- Nadia El-KhawankyNENadia El-Khawanky
- Gabriele IhorstGIGabriele Ihorst
Open Access
- 2 March 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (3) , 1315-1329
Abstract
Acute graft-versus-host disease (GVHD) can affect the central nervous system (CNS). The role of microglia in CNS-GVHD remains undefined. In agreement with microglia activation, we found that profound morphological changes and MHC-II and CD80 upregulation occurred upon GVHD induction. RNA sequencing–based analysis of purified microglia obtained from mice with CNS-GVHD revealed TNF upregulation. Selective TNF gene deletion in microglia of Cx3cr1creER Tnffl/– mice reduced MHC-II expression and decreased CNS T cell infiltrates and VCAM-1+ endothelial cells. GVHD increased microglia TGF-β–activated kinase-1 (TAK1) activation and NF-κB/p38 MAPK signaling. Selective Tak1 deletion in microglia using Cx3cr1creER Tak1fl/fl mice resulted in reduced TNF production and microglial MHC-II and improved neurocognitive activity. Pharmacological TAK1 inhibition reduced TNF production and MHC-II expression by microglia, Th1 and Th17 T cell infiltrates, and VCAM-1+ endothelial cells and improved neurocognitive activity, without blocking graft-versus-leukemia effects. Consistent with these findings in mice, we observed increased activation and TNF production of microglia in the CNS of GVHD patients. In summary, we prove a role for microglia in CNS-GVHD, identify the TAK1/TNF/MHC-II axis as a mediator of CNS-GVHD, and provide a TAK1 inhibitor–based approach against GVHD-induced neurotoxicity.Keywords
Funding Information
- H2020 European Research Council (681012 GvHDCure)
- Deutsche Forschungsgemeinschaft (TRR167 NeuroMAC)
- H2020 European Research Council (681012 GvHDCure)
This publication has 29 references indexed in Scilit:
- Acute Graft-versus-Host Disease — Biologic Process, Prevention, and TherapyNew England Journal of Medicine, 2017
- CD8-predominant T-cell CNS infiltration accompanies GVHD in primates and is improved with immunoprophylaxisBlood, 2014
- A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammationNature Neuroscience, 2013
- The central nervous system is a target of acute graft versus host disease in miceBlood, 2013
- CX3CR1 Protein Signaling Modulates Microglial Activation and Protects against Plaque-independent Cognitive Deficits in a Mouse Model of Alzheimer DiseaseJournal of Biological Chemistry, 2011
- Ubiquitin-mediated activation of TAK1 and IKKOncogene, 2007
- Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB–regulated gene products and TAK1-mediated NF-κB activationBlood, 2006
- Central nervous system graft‐versus‐host disease post allogeneic stem cell transplantBritish Journal of Haematology, 2005
- Functional Interactions of Transforming Growth Factor β-activated Kinase 1 with IκB Kinases to Stimulate NF-κB ActivationJournal of Biological Chemistry, 1999
- Male Donor-derived Cells in the Brains of Female Sex-mismatched Bone Marrow Transplant RecipientsJournal of Neuropathology & Experimental Neurology, 1993